Umeclidinium bromide: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
 
Line 36: Line 36:
[[Category:Quaternary ammonium compounds]]
[[Category:Quaternary ammonium compounds]]
[[Category:Muscarinic antagonists]]
[[Category:Muscarinic antagonists]]
<gallery>
File:Umeclidinium_bromide.svg|Chemical structure of Umeclidinium bromide
File:Umeclidinium_bromide_3D.png|3D model of Umeclidinium bromide
</gallery>

Latest revision as of 00:44, 18 February 2025

A medication used in the management of chronic obstructive pulmonary disease


Umeclidinium bromide
File:Umeclidinium bromide.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Umeclidinium bromide is a medication used in the management of chronic obstructive pulmonary disease (COPD). It is a long-acting muscarinic antagonist (LAMA) that helps to open the airways and make breathing easier.

Medical uses[edit]

Umeclidinium bromide is primarily used as a maintenance treatment for COPD. It is not indicated for the relief of acute bronchospasm or for the treatment of asthma. The medication is administered via inhalation, typically once daily, using a specific inhaler device.

Mechanism of action[edit]

Umeclidinium bromide works by blocking the action of acetylcholine on muscarinic receptors in the airways. This action leads to the relaxation of bronchial smooth muscle, resulting in bronchodilation and improved airflow in patients with COPD.

Side effects[edit]

Common side effects of umeclidinium bromide include dry mouth, cough, and upper respiratory tract infections. Less common but more serious side effects can include urinary retention and paradoxical bronchospasm.

Pharmacokinetics[edit]

After inhalation, umeclidinium bromide is absorbed into the bloodstream, where it reaches peak plasma concentrations within a few hours. It is metabolized primarily by the liver and excreted in the urine and feces.

History[edit]

Umeclidinium bromide was developed by GlaxoSmithKline and was approved for medical use in the United States in 2013. It is often combined with other medications, such as vilanterol, to enhance its therapeutic effects.

Related pages[edit]

References[edit]

<references group="" responsive="1"></references>